Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170008/S059

EluNIR-PERL Ridaforolimus Eluting Coronary Stent System

Medinol, Ltd. · Decision date Aug 7, 2025

FDA DECISIONP170008/S059

What did the FDA decide?

FDA records P170008/S059 as a supplement to PMA P170008, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 7, 2025.

FDA approval order statement

a change to the leak testing procedure
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Aug 7, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P170008/S059
Regulatory pathway
PMA supplement
Applicant
Medinol, Ltd.
Product code
NIQ
Decision code
OK30
Decision date
Aug 7, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Applicant
Medinol, Ltd.
Product code
NIQ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P170008/S059 received

    Application receipt date recorded by FDA.

  2. P170008/S059 · FDA decision

    30-Day Notice

  3. P170008/S060 · Related supplement

    EluNIR Ridaforolimus Eluting Coronary Stent System

  4. P170008/S056 · Related supplement

    EluNIR Ridaforolimus Eluting Coronary Stent System

  5. P170008/S061 · Related supplement

    EluNIR Ridaforolimus Eluting Coronary Stent System

  6. P170008/S062 · Related supplement

    EluNIR Ridaforolimus Eluting Coronary Stent System

  7. P170008/S064 · Related supplement

    EluNIR Ridaforolimus Eluting Coronary Stent System

Timeline entries are records held by MedtechLedger for P170008. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170008

Product / regulatory recordCompanyPathwayDecision dateSource
Medinol, Ltd.PMA supplementAug 15, 2025FDA
Medinol, Ltd.PMA supplementOct 2, 2025FDA
Medinol, Ltd.PMA supplementFeb 4, 2026FDA
Medinol, Ltd.PMA supplementMar 26, 2026FDA
Medinol, Ltd.PMA supplementAug 6, 2026FDA

Explore the linked device profile

Other records with product code NIQ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medinol, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Kiryat Atidim, Bldg. 8, P.O.B. 58165, Tel Aviv, 6158101

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records